Celladon is dedicated to the treatment of cardiac diseases through the use of new technologies in molecular cardiology. Celladon’s products are first-in-class drugs that target the key enzyme deficiency in severe heart failure, SERCA2a. A major underpinning of heart failure is the depletion of SERCA2a enzyme in heart muscle cells, which results in abnormal intracellular calcium cycling and poor contractility. Our research shows that recombinant adeno-associated viral (AAV) vectors are ideal for restoring SERCA2a enzyme production via gene transfer to cardiac muscle cells.
Click on the links below for Celladon's Product Overview.
...The mean duration of hospitalization in the MYDICAR® high dose group during the 12-month period was 0.4 days per patient compared with 4.5 days per patient in the placebo group. This finding is especially noteworthy because heart failure is the leading cause of hospitalization in Americans 65 years of age and older...